Forskningsprojekter

Using cell sorting and a multiomics approach, we are investigating the biology and kinetics of residual leukemia cells treated with a Bruton’s tyrosine kinase inhibitor

_{Relevant publications:}

_{A Case-Driven Multi-Omics Analysis for Longitudinal Ibrutinib Response Evaluation of Patients With Chronic Lymphocytic Leukemia.
Veyhe SR, Hansen MH, Cédile O, Møller MB, Nielsen MK, Thomassen M, Juul-Jensen K, Frederiksen H, Dybkær K, Nyvold CG. Eur J Haematol. 2025
Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia.
Veyhe SR, Cédile O, Dahlmann SK, Krejcik J, Abildgaard N, Høyer T, Møller MB, Thomassen M, Juul-Jensen K, Frederiksen H, Dybkær K, Hansen MH, Nyvold CG. Int J Mol Sci. 2024}

Profiling of circulating tumor DNA employed in sensitive, longitudinal assessment of treatment response

_{Relevant publications:}

_{Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics.
Vimalathas G, Hansen MH, Cédile O, Thomassen M, Møller MB, Dahlmann SK, Kjeldsen MLG, Hildebrandt MG, Nielsen AL, Naghavi-Behzad M, Edenbrandt L, Nyvold CG, Larsen TS. Blood Adv. 2025
Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non-Hodgkin Large B-Cell Lymphoma: A Comparative Study of Cell-Free DNA and Formalin-Fixed Paraffin-Embedded Tissue.
Vimalathas G, Cédile O, Kjeldsen MLG, Thomassen M, Møller MB, Nyvold CG, Hansen MH, Larsen TS. Int J Lab Hematol. 2025
Cell-free DNA for detection of clonal B cells in diffuse large B cell lymphoma by sequencing.
Højlund EL, Cédile O, Larsen TS, Vimalathas G, Møller MB, Hansen MH, Nyvold CG. Int J Lab Hematol. 2023}

Ultra‑deep sequencing of clonal immunoglobulin receptor rearrangements for the assessment of minute levels of residual disease in B cell malignancies.

_{Relevant publications:
SWIGH-SCORE: A translational light-weight approach in computational detection of rearranged immunoglobulin heavy chain to be used in monoclonal lymphoproliferative disorders.
Hansen MH, Maagaard M, Cédile O, Nyvold CG.MethodsX. 2024.
Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing.
Cédile O, Hansen MH, Dahlmann SK, Kristensen TK, Abildgaard N, Nyvold CG.Exp Hematol. 2023.
Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing.
Elkjær LAL, Cédile O, Hansen MH, Nielsen C, Møller MB, Abildgaard N, Haaber J, Nyvold CG.Leuk Res Rep. 2022.
Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?
Hansen MH, Cédile O, Larsen TS, Abildgaard N, Nyvold CG.Exp Hematol. 2021.}

This CITCO project focuses on the exhaustive examination of B cell profiles, employing both pre-clinical and clinical approaches to gain deeper insights into the characsteristics of B cell cancers with the focus of finding novel targets to extend the efficact of treatments.

In collaboration with Centre for Cellular Immunotherapy of Haematological Cancer Odense CITCO

Third-generation sequencing is implemented for flexible high-precision clonotyping of malignant B cells and in progressing the field of cytogenomics

_{Relevant publications:}

_{Performance of Rapid Clonotyping of Chronic Lymphocytic Leukemia Using Flongle Flow-Cell Nanopore Sequencing of IGH Rearrangements.
Hansen MH, Gulmir R, Cédile O, Dahlmann SK, Veyhe SR, Stougaard M, Juul-Jensen K, Nyvold CG. Eur J Haematol. 2025
The potential of 3rd-generation nanopore sequencing for B-cell clonotyping in lymphoproliferative disorders.
Hansen MH, Cédile O, Abildgaard N, Nyvold CG. EJHaem. 2023
Toward Cytogenomics: Technical Assessment of Long-Read Nanopore Whole-Genome Sequencing for Detecting Large Chromosomal Alterations in Mantle Cell Lymphoma.
Hansen MH, Cédile O, Kjeldsen MLG, Thomassen M, Preiss B, von Neuhoff N, Abildgaard N, Nyvold CG. J Mol Diagn. 2023}

Investigates how MSCs contribute to bone loss and impaired healing in multiple myeloma by uncovering transcriptional and functional MSC alterations

_{Relevant publications:
Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study.
Levring MB, Diaz-delCastillo M, Gundesen MT, Cédile O, Andersen CW, Nielsen AL, Møller HEH, Vinholt PJ, Asmussen JT, Kristensen IB, Nyvold CG, Kassem M, Abildgaard N, Andersen TL, Lund T. Bone. 2025
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Johansen M, Levring MB, Stokbro K, Diaz-delCastillo M, Khan AA, Wickstroem LA, Gundesen MT, Kristensen IB, Nyvold CG, Andersen MØ, Andersen TL, Abildgaard N, Lund T. Cancers (Basel). 2023}

Investigates the changes in the T-cell compartment after treatment with engineered antibodies that make T cells recognize and kill the cancer cells

_{Relevant publication:}

_{Harnessing the Immune System to Fight Multiple Myeloma.
Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T, Abildgaard N. Cancers (Basel). 2021}